ABBV-927 + ABBV-368 + budigalimab

**ABBV-927 + ABBV-368 + budigalimab** is a combination of three investigational monoclonal antibody drugs developed by AbbVie for the treatment of advanced solid tumors, including *non-small cell lung cancer (NSCLC)* and *triple-negative breast cancer (TNBC)*[2][3][6]. - **ABBV-927 (giloralimab)** is a CD40 agonist monoclonal antibody that stimulates both innate and adaptive immunity, essential for T-cell activation and proliferation[2]. - **ABBV-368 (revdofilimab)** is an OX40 agonist monoclonal antibody that boosts nascent immune responses and suppresses regulatory T-cell activity, enhancing overall antitumor immunity[2]. - **budigalimab (ABBV-181)** is a monoclonal antibody inhibitor of programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to restore T-cell function and facilitate antitumor activity[2]. This combination is administered via intravenous infusion and is under evaluation in phase 1 clinical trials for locally advanced or metastatic solid tumors, with key endpoints including safety, tolerability, pharmacokinetics, and preliminary efficacy. Recruitment started in 2019 and is ongoing, with AbbVie as the sole developer and sponsor[1][2][5][6][7].